International Stem Cell Corp. (ISCO.OB) Teams with The Automation Partnership to Accelerate and Ramp-up Synthetic Corneal Tissue

In the company’s news yesterday,

International Stem Cell Corp. announced its strategic alliance with The Automation Partnership (TAP) to automate and increase the production of stem cell-derived human corneal tissue to produce commercial volumes of the tissue for cornea transplants and to reduce the use of animals in product testing.

TAP provides advanced automation systems and services to improve productivity in life science research, development and production. TAP CEO David Newble said the partnership enforces its efforts to provide equipment for life science applications, and gives it an entrance to the biomedical market.

“TAP has successfully installed and supported over 160 automated cell culture systems worldwide and continues to design new and customize existing equipment for cell culture and other emerging life science applications. The opportunity to join forces with ISCO in the cornea tissue area will enable us to contribute solutions for clear biomedical needs while also creating new technology and knowhow that will be useful in other applications downstream,” Newble stated in the press release.

ISCO has filed for patents for its discoveries on the cell culture process for the synthesis of standardized, human, corneal tissue using stem cells. The company focuses on addressing the needs for corneal tissue for transplants and is working to raise awareness of its technology to a diverse demographic.

“Given the substantial unmet therapeutic and toxicology testing needs for human corneal tissue, ISCO has embarked on a focused effort to advance this technology with international investors, eye clinics, and development and commercialization partners. After reviewing a range of potential cell culture automation companies, we are very pleased that TAP has agreed to contribute their over twenty years of experience toward this goal,” Brian Lundstrom, ISCO’s president stated.

TAP and International Stem Cell’s focus correlate with global efforts to steer away from the use of live animals to test drugs, chemicals and consumer products. According to the press release, Europe’s Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) estimates that it needs to use 160,000 animals for eye safety testing alone simply to catch up with the back-log of insufficiently tested agents; and in the United States, the National Institutes of Health (NIH) and the Environmental Protection Agency (EPA) have initiated a five-year program to find new, non-animal technologies for toxicity testing of chemical compounds.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.